Recombinant Human Sodium-dependent noradrenaline transporter (SLC6A2), partial

1. Our case-control study and meta-analysis suggest that the NET gene G1287A polymorphism may not be involved in the etiology of schizophrenia in the Chinese Han population PMID: 29431473
2. genetic association/pharmacogenetic studies in population in Switzerland: Data from controlled studies suggest that SNPs in SLC6A2 (rs1861647, rs2242446, rs36029) weakly moderate acute cardiovascular response to MDMA (methylenedioxymethamphetamine, "ecstasy") and may play minor role in adverse cardiovascular events when MDMA is used recreationally. PMID: 29198060
3. Our study indicates that DNA methylation levels of nine CpG sites in NET gene promoter region are not associated with depression and hypertension. PMID: 28737436
4. case-control study by genotyping 7 SNPs of SLC6A2, SLC6A3 and DRD2 in 1034 schizophrenia patients and 1034 controls. No significant difference in the allelic or genotypic frequency was detected between cases and controls PMID: 28454051
5. nine ADHD candidate single nucleotide polymorphisms (SNPs) in seven genes were tested for association with PD in 5333 cases and 12,019 healthy controls. No significant association was observed. PMID: 28176268
6. T allele of the SNP rs7194256 in the 3'UTR of the NET gene is more prevalent in diseases where NET impairment is evident, including essential hypertension, depression, panic disorder and postural orthostatic tachycardia syndrome; mechanism involved may include the creation of a binding site for the miRNA miR-19-3p, which is, at least in part, regulated by circulating norepinephrine concentrations PMID: 27046647
7. Polymorphisms of COMT (c.649G>A), MAO-A (c.1460C>T), NET (c.1287G>A) Genes and the Level of Catecholamines, Serotonin in Patients with Parkinson's Disease PMID: 28418735
8. NET rs2242446/T-182C may serve as a biomarker to predict the likelihood of remission with venlafaxine in older adults with major depression. These findings may help to optimize antidepressant outcomes in older adults. PMID: 28068779
9. These results suggest that NET polymorphism may affect the SNRI response in Korean panic disorder patients. PMID: 26508020
10. Imaging genetic study showed significant differences in NET nondisplaceable binding potential in patients with attention deficit hyperactivity disorder compared to healthy controls, depending on their genotype PMID: 26678348
11. NET undergoes extensive constitutive internalization and internalized NET mainly is sorted to Rab11-positive recycling endosomes. PMID: 26786096
12. In Major Depressive Disorder patients there seems to be a relationship between the volume of the dorsolateral prefrontal cortex and polymorphism of the SLC6A2 G1287A gene. PMID: 26960194
13. This corticotropin releasing factor-induced regulation on norepinephrine transporter expression and function may play a role in development of stress-related depression and anxiety PMID: 26212818
14. Study identified the haplotype rs36011 (T)/rs1566652 (G) as a novel genetic marker involved in both attention-deficit/hyperactivity disorder disease susceptibility and visual memory PMID: 25554436
15. a NET 182C and 5-HTTLPR polymorphism interaction is associated with susceptibility to treatment resistant depression and ECT treatment response in antidepressant resistant depression patients PMID: 25650523
16. NET gene variants are not involved in the etiology of recurrent major depressive disorder in Chinese Han population. PMID: 26051731
17. Different combinations of T-182C and the G1287A polymorphisms of NET gene might increase morbidity risk of major depression subpopulations PMID: 26061302
18. A Cox regression analysis for remission incidence during the 8-week treatment course significantly depends on SLC6A2 variants (rs28386840, rs40434, and rs187714)from major depression after venlafaxine treatment. PMID: 25512257
19. The response to venlafaxine was assessed after 4 weeks of treatment and correlated to serum concentration and functional variants in genes encoding SLC6A2 and SLC6A4 PMID: 25295552
20. The rs2242446 genotype, coded additively as the number of minor (G) alleles, significantly predicted both scale scores and count of anxious arousal symptoms but none of the other symptom clusters or severity or probable diagnosis of PTSD. PMID: 25919853
21. polymorphisms of 1287G/A, -182T/C and -3081A/T in the norepinephrine transporter gene are not risk factors in alcohol dependence. PMID: 25831948
22. The results of this study do not support the association between the SLC6A2 and the diagnosis or phenotype of autism spectrum disorder. PMID: 24381062
23. results do not indicate involvement of changes in brain Norepinephrine Transporter availability or distribution in the pathogenesis of Attention deficit/hyperactivity disorder. PMID: 25338091
24. Our results suggest that SLC6A2 polymorphisms were associated with suicide risk in patients with major depressive disorder. PMID: 24655776
25. Data indicate that [(18)F]-MFBG PET imaging shows higher sensitivity, better detection of small lesions with low NET protein expression. PMID: 24573553
26. The family-based study showed no association between the CNTFR rs7036351, NET rs3785143 polymorphisms, and attention-deficit hyperactivity disorder. PMID: 24565995
27. meta-analysis did not suggest a confirmed association between the T-182C polymorphism of the NET gene and major depressive disorder. PMID: 24374057
28. Duloxetine significantly affected norpepinephrine turnover in the central nervous system and periphery; these effects presumably occurred via inhibition of reuptake by NET, as indicated by effects on functional reuptake inhibition ex vivo. PMID: 24346757
29. Report NET occupancy in human thalamus after oral administration of quetiapine XR. PMID: 23809226
30. The results do not suggest SLC6A2 as a susceptibility gene for depression in the Danish population. PMID: 23969988
31. The results of this study suggest that DNA variants of both SLC6A2 and ADRA2A in the adrenergic neurotransmitter system might alter the response to atomoxetine. PMID: 23266789
32. NK1R forms physical complexes with NET. PMID: 23979140
33. Our findings suggest that the norepinephrine transporter T-182C and G1287A polymorphisms are not susceptibility factors for major depressive disorder. PMID: 23648227
34. Haplotype analysis demonstrates a significant association between attention deficit hyperactivity disorder (ADHD) and SLC6A2 gene. PMID: 23052569
35. a comprehensive phenotype/genotype analyses of the norepinephrine transporter gene (SLC6A2) in ADHD shows a relationship to maternal smoking during pregnancy PMID: 23185385
36. Our results provide evidence for the possible role of the G1287A and A-3081T genotypes of SLC6A2 in methylphenidate-induced improvement in attentional performance and support the noradrenergic hypothesis for the pathophysiology of ADHD. PMID: 22591463
37. Analysis of drug sensitivity profiles provides novel information on drug binding modes in hSERT and hNET and identifies specific S1 residues as important molecular determinants for inhibitor potency and hSERT/hNET selectivity. PMID: 23086945
38. SLC6A2 promoter-3-GA/GG genotype may be a susceptibility gene for patients of essential hypertension with severe blood-stasis pattern. PMID: 20681272
39. chromatin-modifying events associated with SLC6A2 gene suppression may constitute a mechanism of postural tachycardia syndrome PMID: 22723437
40. This study demonistrated that the noradrenaline (SLC6A2) transporter polymorphisms may have an effect on response to kava. PMID: 22311378
41. Our results indicate that both neural endophenotypes and genetic variation in SLC6A2 give rise to the various manifestations of impulsive behavior PMID: 22544311
42. In our Caucasian study cohort the presence of the minor rs168924 single-nucleotide polymorphism in the SLC6A2 was associated with lower prevalence of hypertension. PMID: 22533655
43. Although the results of this study should be interpreted cautiously, they suggest that polymorphisms of the NET gene may contribute to an intermediate phenotype of attention deficit/hyperactivity disorder. PMID: 22405810
44. family-based study suggest that haplotype blocks within different regions of SLC6A2 show differential association with ADHD based on sex and subtype PMID: 22297068
45. SLC6A2 is involved in clearing extracellular norepinephrine from the synaptic cleft. PMID: 21070505
46. The norepinephrine transporter could be a susceptibility gene for Parkinson disease. PMID: 21416264
47. Norepinephrine, active norepinephrine transporter, and norepinephrine-metabolism are involved in the generation of reactive oxygen species in human ovarian granulosa cells PMID: 22234472
48. the present study showed no association of a functional variant, capable to downregulate the expression of SLC6A2, in a German family-based ADHD sample. PMID: 21739117
49. Data show that ten of the 18 high-scoring drugs tested experimentally were found to be NET inhibitors. PMID: 21885739
50. Dexamethasone-induced increase in NET expression is mediated by the glucocorticoid receptor via a transcriptional mechanism involving interaction of C/EBP-beta with a C/EBP-beta response element. PMID: 21883217

Show More

Hide All

HGNC: 11048

OMIM: 163970

KEGG: hsa:6530

STRING: 9606.ENSP00000219833

UniGene: Hs.78036